Takeda Drug Patent Suit Seeks to Block Qilu’s Copy of Livtencity

Qilu Pharmaceutical (Hainan) Co.’s proposed copy of Livtencity infringes six patents for the Takeda Pharmaceutical Co. drug, used to treat serious viral infections in transplant patients, a federal lawsuit said.

Takeda alleged the Qilu generic 200-milligram tablets of maribavir, Livtencity’s active ingredient, infringe US Patent Nos. 11,684,632, 12,213,989, 12,295,940, 12,433,907, 12,447,169, and 12,447,170, in a complaint filed Wednesday in the US District Court for the District of New Jersey.

The US Food and Drug Administration approved Livtencity in November 2021 for treating certain organ and stem cell transplant recipients with cytomegalovirus, or CMV, a ...